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Abstract
Complementary and alternative medicine, includ-
ing Traditional Chinese Medicine (TCM), has been
used as therapy against acquired immune deficien-
cy syndrome (AIDS) for almost 30 years. Based on
evaluation indicators for AIDS treatment using
TCM, we discuss why the survival rate (which has
been used widely in Western Medicine) should be
adopted as a new important indicator of TCM treat-
ment for AIDS. We advise that further prospective
or retrospective cohort studies should be carried
out to confirm this hypothesis.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
In China, the first patients with human immunodefi-
ciency virus (HIV)/acquired immune deficiency syn-
drome (AIDS) were reported in Beijing in 1985.1 From
1985 onwards some practitioners of Traditional Chi-
nese Medicine (TCM) began to treat AIDS with the
hope of cure, whereas others sought to explore integra-
tive-medicine methods to treat AIDS.
Since 2003, the State Administration of Traditional
Chinese Medicine has sponsored a pilot program to
treat AIDS patients with TCM in conjunction with an-
ti-retroviral drugs.2 Some endpoints had been used to
evaluate the effects of TCM for the treatment and re-
search of AIDS: symptoms and signs;3 quality of life
(QoL),4 CD4+ T-cell counts;5 plasma viral load (PVL)
of HIV.6
In this review, after analyzing the evaluation methods
of HIV/AIDS with combination anti-retroviral therapy
(cART) plus TCM, we recommend the survival rate as
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an endpoint for evaluating the effectiveness of TCM
treatment against AIDS.
ADVANCES INTCMTHERAPY FOR
AIDS
Since 1996, the prevalencemortality and morbidity be-
cause of HIV/AIDS has been reduced thanks to cART.7
The latter involves therapy over the lifetime of a pa-
tient, so some limitations have been observed: adverse
effects of drugs, drug resistance, and the high cost of
treatment. Therefore, researchers have been looking for
new cART agents, and have investigated complementa-
ry and alternative medicine (CAM).8
TCM has been used for thousands of years. Some of in-
fectious diseases have been treated successfully by
TCM: severe acute respiratory syndromes,9 influenza A
virus subtype H1N1,10 epidemic encephalitis,11 and
hepatitis.12
According to TCM theory, AIDS is an infectious dis-
ease. AIDS leads not only to an imbalance in yin and
yang but also disharmony of internal pathophysiologic
functions and the external natural environment. In
terms of TCM, the management strategy is to regain a
new dynamic balance of yin and yang through pattern
identification to recuperate and avoid further damage.
TCM had been used to treat AIDS for nearly 30 years.
Some scholars are convinced of its effectiveness against
AIDS through: reduction of PVL; increasing CD4 +
T-cell counts; promotion of reconstitution of immuni-
ty; improving health-related quality of life
(HRQOL).13
However, there is insufficient evidence to support the
use of herbal medicines against HIV. We face some
challenges: limited knowledge for using TCM to treat
AIDS; lack of well-designed and well-controlled clini-
cal studies.
EVALUATION INDICATORS OF AIDS
TREATMENT USINGTCM
According to Western Medicine (WM), AIDS is
caused by HIV infection. If the infection is not detect-
ed and treated, the immune system is gradually weak-
ened, which leads to the development of AIDS. In the
human body, the CD4 + T Cell is the immune cell
damaged by HIV. How to eliminate, diminish or sup-
press the HIV load and to strengthen the immune sys-
tem are the two most important goals for WM using a
cART strategy to restore immune function, prevent op-
portunistic infections, and reduce the mortality.14
Thus, CD4+T-cell counts and HIV loads were initially
recommended as primary indicators for evaluation of
treatment by the World Health Organization,15 and
have been used widely.
Since 1996, HIV-related mortality and morbidity has
been greatly reduced by cART, and the lives of patients
prolonged. However, the prevalence of HIV-related
and non-HIV-related diseases and symptoms among
those patients has increased. Patients are not merely
content with improvement of CD4+ T-cell counts and
suppression of PVL, they are motivated by better QoL
and fewer side-effects of cART.
Thus, some new indicators have been used to evaluate
treatment besides CD4+T-cell counts and HIV loads
in some studies on cART: HRQOL; troublesome symp-
toms and signs such as fatigue, insomnia, dementia, fe-
ver, and diarrhea; and mental and spiritual disor-
ders.16-18 To some extent, such changes reflect a focus
on the demands on the patient rather than HIV and the
immune system as the ultimate goal of AIDS treatment.
By contrast, TCM practitioners focus on the symp-
toms of the patients. They use such symptoms as evalu-
ation indicators if they treat/change their strategy for
AIDS patients, and if they research AIDS or AIDS-re-
lated diseases.19-21
FEASIBILITY OF USING SURVIVAL
RATE FOR EVALUATIONOFTCM
THERAPY AGAINST AIDS
Besides the evaluation indicators mentioned above, the
survival rate of HIV/AIDS patients is an important in-
dicator that can be used to evaluate the treatment ef-
fects of TCM against AIDS. However, there have been
no reports on this outcome, and there are four main
reasons for this knowledge gap.
First, AIDS remains a chronic and potentially fatal dis-
ease. The mortality of HIV/AIDS has been reduced ow-
ing to cART, and life expectancy among HIV/AIDS pa-
tients is increasing. Thus, the survival rate is as impor-
tant as that mortality. More attention should be paid
to improving survival and reducing mortality.
Second, AIDS is a very complex disease. Many factors
affect disease progression and the survival of people liv-
ing with HIV: age,22 sex,23 immune function,24 nutri-
tional status,25 risk factors for HIV,26 disease stage,27
complications,28 timing of cART,29 and geographic loca-
tion.30 Multiple effects of TCM on HIV/AIDS have
been reported. Some Chinese patients use TCM for
the prevention and treatment of disease as well as
healthcare because it is convenient, inexpensive and ef-
fective. If AIDS/HIV patients also use TCM, it may
improve their chance of survival.
Third, use of cART has strict indications and contrain-
dications. Some HIV/AIDS patients have no choice
but to use TCM or other methods because they are not
suitable for cART, or because they had to stop cART
owing to liver disease, kidney disease, or drug resis-
tance. More importantly, the risk of death increases for
HIV/AIDS patients who are not being treated. In this
situation, TCM therapy against AIDS is particularly
important to reduce the risk of mortality and prolong
life.
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Fourth, from 2004 onwards, the State Administration
of Traditional Chinese Medicine of China undertook a
pilot program for the use of TCM to treat AIDS pa-
tients in conjunction with anti-retroviral drugs. In this
way, more than 10 000 HIV/AIDS patients benefited
from free TCM treatment in 19 provinces (including
autonomous regions and municipalities). By the end
of November 2011, different cohorts had been creat-
ed and considerable data collected. In the same peri-
od, some cART-related cohorts in different provinces
had been created. Therefore, survival analyses could
be used to undertake a retrospective study to explore
the effect of TCM on the survival of HIV/AIDS pa-
tients. If TCM is shown to improve the survival of
AIDS/HIV patients, these results will increase (or
eliminate) prejudice against use of TCM against
AIDS, and encourage more patients to accept such
treatment.
There are some useful evaluation indicators for AIDS
treatment, but we recommend survival analysis (which
has been used widely in WM) as a new and important
indicator for TCM treatment against AIDS. We advise
researchers to use survival analysis to evaluate the effect
of TCM on prolonging the survival of AIDS patients.
EVALUATIONOF SURVIVAL
Survival rate is defined as the percentage of patients
alive with or without treatment after a given period of
follow-up (usually 1, 3, or 5 years).31 Survival rate is im-
portant for the prognosis, and can be used to (a) de-
scribe the lethality of the disease and (b) evaluate the
long-term curative effect. Survival rate is often used in
chronic diseases such as cancer,32 cardiovascular disease,33
or tuberculosis,34 but it has also been used to evaluate
the effect of cART or other management strategies. Sur-
vival of AIDS patients can be prolonged not only by a
cART strategy but also by the other methods.35 Various
types of survival rate have been used as endpoints in
clinical trials.
"Overall survival" is the time from the diagnosis to the
time of death owing to any cause. Researchers often
use mean overall survival to estimate the prognosis,
and is often expressed over standard time periods (usu-
ally 1, 3, 5, or 10 years). If there is a small increase in
survival, this can be considered to be clinical evidence
of the benefits of a certain type of treatment.
"Net survival" is the time from the diagnosis to the
time of death due to the disease, which filters out the
effect of mortality from causes other than the disease.
There are two main ways to calculate net survival: "rela-
tive survival" and "cause-specific survival" ("disease-spe-
cific survival"). Relative survival has the advantage of
not being dependent upon accurately knowing the
cause of death. It is calculated by dividing the overall
survival after the diagnosis by the survival as observed
in a similar population without the disease. A "similar
population" comprises individuals with at least age and
sex similar to those diagnosed with the disease.
Cause-specific survival has the advantage that it is not
dependent upon finding a similar population of people
without the disease. It can be calculated by treating
deaths from other causes than the disease as withdraw-
als from the population that do not lower survival com-
pared with patients who are not being observed any
more (e.g. owing to reaching the end of the study period).
"Median survival" is also used in regard to survival if
the mean survival is relatively short (i.e., the amount of
time at which 50% of patients have died and 50%
have survived). For example, median survival of six
months indicates that, after 6 months, 50% of people
with that condition will be alive and 50% will have
died.
One-, three-, or five-year survival measures survival at
1, 3 or 5 years, respectively, after the diagnosis. For ex-
ample, if 5-year survival is 85% , then 85 out of 100
people with a certain disease will be alive after 5 years.
Besides HIV/AIDS-related reasons, cause of death is
quite complex among patients. Hence, confirming the
cause of death is quite difficult. Overall survival is
much easier to calculate than net survival, but the lat-
ter is much more exact if studying the relationship be-
tween survival and the effect of HIV/AIDS. AIDS has
a mean duration of 8-10 years from infection to death
without timely and effective therapy. Hence, not only
the 1-, 3-, or 5-year survival but also median survival is
used scarcely. Hence, in studies of the effect of TCM
on HIV/AIDS, we recommend overall survival and net
survival as evaluation indices.
As mentioned above, many factors simultaneously af-
fect disease progression and the survival of people liv-
ing with AIDS/HIV, and it is difficult to distinguish
which are risk factors and protective factors in differ-
ent studies. We should take multiple factors into ac-
count when employing analyses to ascertain if an in-
tervention increases the survival of AIDS/HIV pa-
tients.
CONCLUSION
AIDS is a worldwide public-health problem. Roles of
TCM against AIDS are being accepted by increasing
numbers of patients. There are many differences be-
tween TCM and WM in terms of philosophy, but we
believe that the survival rate of HIV/AIDS patients af-
ter TCM treatment could be a new indicator for assess-
ing the efficacy of such treatment.
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